Stock Research: Novo Nordisk

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Novo Nordisk

CPH:NOVO B DK0060534915
4
  • Value
    41
  • Growth
    1
  • Safety
    Safety
    27
  • Combined
    4
  • Sentiment
    16
  • 360° View
    360° View
    4
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Novo Nordisk A/S is a global healthcare company specializing in diabetes care, and the development, manufacturing, and marketing of pharmaceutical products. It operates in the diabetes and obesity care, and biopharmaceuticals industries, with products like NovoLog/NovoRapid and NovoSeven. The company markets its products in over 180 countries, with commercial units in North America and International Operations. In the last fiscal year, the company had a market cap of $300970 million, profits of $34273 million, and revenue of $40321 million, with 76302 employees.

more
Index
OMX C20
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
41 12 9 12
Growth
1 42 99 69
Safety
Safety
27 26 48 68
Sentiment
16 34 30 8
360° View
360° View
4 7 37 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
18 42 28 9
Opinions Change
28 31 52 34
Pro Holdings
n/a 87 82 74
Market Pulse
17 24 15 17
Sentiment
16 34 30 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
41 12 9 12
Growth
1 42 99 69
Safety Safety
27 26 48 68
Combined
4 7 54 48
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
41 7 7 13
Price vs. Earnings (P/E)
31 14 11 17
Price vs. Book (P/B)
10 1 1 1
Dividend Yield
84 68 61 61
Value
41 12 9 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
9 89 79 61
Profit Growth
42 65 84 54
Capital Growth
4 16 82 29
Stock Returns
5 12 94 92
Growth
1 42 99 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
24 25 52 65
Refinancing
1 6 11 12
Liquidity
86 86 85 85
Safety Safety
27 26 48 68

Similar Stocks

Discover high‑ranked alternatives to Novo Nordisk and broaden your portfolio horizons.

STMicroelectronics

PAR:STMPA
Country: Netherlands
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

MOL

BUD:MOL
Country: Hungary
Industry: Oil & Gas Integrated
Size: X-Large
Full Stock Analysis

Ternium

NYQ:TX
Country: Netherlands
Industry: Steel
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: